Enanta Pharmaceuticals, Inc.
ENTA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $256 | $161 | $118 | $122 |
| - Cash | $32 | $45 | $60 | $84 |
| + Debt | $201 | $207 | $216 | $221 |
| Enterprise Value | $425 | $323 | $274 | $259 |
| Revenue | $15 | $18 | $15 | $17 |
| % Growth | -17.4% | 22.7% | -12% | – |
| Gross Profit | $15 | $18 | $15 | $17 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$16 | -$15 | -$21 | -$20 |
| % Margin | -107.6% | -84.1% | -140.9% | -117.1% |
| Net Income | -$19 | -$18 | -$23 | -$22 |
| % Margin | -123.6% | -99.7% | -151.7% | -131.4% |
| EPS Diluted | -0.87 | -0.85 | -1.06 | -1.05 |
| % Growth | -2.4% | 19.8% | -1% | – |
| Operating Cash Flow | – | $18 | -$13 | -$17 |
| Capital Expenditures | – | -$0 | -$3 | -$9 |
| Free Cash Flow | – | $17 | -$16 | -$26 |